Literature DB >> 9420682

Effects of altered left ventricular geometry on quantitative technetium 99m sestamibi defect size in humans: perfusion imaging during coronary angioplasty.

H L Haronian1, A J Sinusas, M S Remetz, J J Brennan, H S Cabin, B L Zaret, F J Wackers.   

Abstract

BACKGROUND: Serial myocardial perfusion imaging is used to assess exercise-induced myocardial ischemia and myocardial risk area, salvage, and viability in patients with myocardial infarction. In an experimental animal model it has been shown that abnormal regional wall motion and altered left ventricular geometry can produce apparent perfusion defects independent of changes in blood flow. The effects of regional alteration in ventricular geometry on perfusion images in humans are not defined. The purpose of our investigation was to evaluate quantitatively the effect of altered left ventricular geometry on myocardial perfusion imaging with technetium 99m sestamibi during coronary angioplasty. METHODS AND
RESULTS: Nine patients with normal baseline left ventricular function referred for angioplasty of the left anterior descending coronary artery were studied. 99mTc sestamibi was administered intravenously before angioplasty. Baseline planar electrocardiographic-gated imaging was performed. Imaging was repeated in the catheterization laboratory during angioplasty vessel occlusion when altered left ventricular geometry was produced and again later after angioplasty. Summed static, end-systolic, and end-diastolic images were generated from the electrocardiographic-gated acquisitions. Circumferential count profiles of images obtained during percutaneous transluminal coronary angioplasty (PTCA) were compared with those of a normal 99mTc sestamibi database and their own baseline images. Defect integral (the area below the reference profile) and nadir (maximum percent decrease in activity) were derived. Compared with a normal database, new quantitative defects appeared on PTCA-summed images in only two patients. The defects were small to moderate in size. However, compared with their own baseline profile, six patients had quantitative defects during PTCA (mean defect integral 3 +/- 2; mean defect nadir 12% +/- 7%). Defect nadir was larger on end-diastolic images compared with summed images (22% +/- 7% and 12% +/- 7%, respectively; p < 0.05).
CONCLUSIONS: Altered left ventricular geometry may create apparent, albeit small, planar myocardial perfusion defects in humans. Changes in defect size on serial images may be only partially caused by changes in regional wall motion or geometry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9420682     DOI: 10.1007/bf02984087

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  17 in total

1.  Reproducibility of quantitative planar thallium-201 scintigraphy: quantitative criteria for reversibility of myocardial perfusion defects.

Authors:  S L Sigal; R Soufer; R C Fetterman; J A Mattera; F J Wackers
Journal:  J Nucl Med       Date:  1991-05       Impact factor: 10.057

2.  Computer modeling of planar myocardial perfusion imaging: effect of heart rate and ejection fraction on wall thickness and chamber size.

Authors:  J Machac; H Levin; E Balk; S F Horowitz
Journal:  J Nucl Med       Date:  1986-05       Impact factor: 10.057

3.  Quantitative planar thallium-201 stress scintigraphy: a critical evaluation of the method.

Authors:  F J Wackers; R C Fetterman; J A Mattera; J P Clements
Journal:  Semin Nucl Med       Date:  1985-01       Impact factor: 4.446

4.  Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy.

Authors:  F J Wackers; R J Gibbons; M S Verani; D S Kayden; P A Pellikka; T Behrenbeck; J J Mahmarian; B L Zaret
Journal:  J Am Coll Cardiol       Date:  1989-10       Impact factor: 24.094

5.  Validation of continuous radionuclide left ventricular functioning monitoring in detecting silent myocardial ischemia during balloon angioplasty of the left anterior descending coronary artery.

Authors:  D S Kayden; M S Remetz; H S Cabin; L I Deckelbaum; M W Cleman; F J Wackers; B L Zaret
Journal:  Am J Cardiol       Date:  1991-06-15       Impact factor: 2.778

6.  Impact of regional ventricular function, geometry, and dobutamine stress on quantitative 99mTc-sestamibi defect size.

Authors:  A J Sinusas; Q Shi; P J Vitols; R C Fetterman; P Maniawski; B L Zaret; F J Wackers
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

7.  Gated SPECT with technetium-99m-sestamibi for assessment of myocardial perfusion abnormalities.

Authors:  F Mannting; M G Morgan-Mannting
Journal:  J Nucl Med       Date:  1993-04       Impact factor: 10.057

8.  Progressive decrease in myocardial ischemia assessed by intracoronary electrocardiogram during successive and prolonged coronary occlusions in angioplasty.

Authors:  R Koning; A Cribier; L Korsatz; G Stix; C Chan; H Eltchaninoff; B Letac
Journal:  Am Heart J       Date:  1993-01       Impact factor: 4.749

9.  Silent ischemia during coronary occlusion produced by balloon inflation: relation to regional myocardial dysfunction.

Authors:  D Wohlgelernter; C C Jaffe; H S Cabin; L A Yeatman; M Cleman
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

10.  Regional myocardial dysfunction during coronary angioplasty: evaluation by two-dimensional echocardiography and 12 lead electrocardiography.

Authors:  D Wohlgelernter; M Cleman; H A Highman; R C Fetterman; J S Duncan; B L Zaret; C C Jaffe
Journal:  J Am Coll Cardiol       Date:  1986-06       Impact factor: 24.094

View more
  1 in total

1.  Selective intracoronary injection of sestamibi to detect myocardial viability: Prediction of perfusion and contractile recovery after percutaneous transluminal coronary angioplasty.

Authors:  Carlo Trani; Alessandro Giordano; Antonella Lombardo; Alessandro Lupi; Francesca Reale; Roberto Patrizi; Giampiero Patrizi; Mario A Mazzari; Giovanni Schiavoni; Attilio Maseri
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.